Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2.
Shaswath S ChandrasekarYashdeep PhanseMariah RielRachel E HildebrandMostafa HanafyJorge E OsorioSherein Saied AbdelgayedAdel M TalaatPublished in: Viruses (2022)
Antibody measurements are primarily used to evaluate experimental and approved COVID-19 vaccines, which is unilateral considering our immune responses' complex nature. Previously, we showed that nanoparticle plasmid DNA adjuvant system, QAC, and MVA based vaccines were immunogenic against SARS-CoV-2. Here, we report on the protective efficacy of systemic humoral and mucosal cell-mediated immune responses in transgenic mice models against SARS-CoV-2 following nanoparticle immunization. Parenteral, intramuscular administration of QAC-based plasmid DNA vaccine-encoding SARS-CoV-2 S and N led to the induction of significant serum neutralizing humoral responses, which reduced viral burden in the lungs and prevented viral dissemination to the brain. In contrast, the mucosal, intranasal administration of a heterologous vaccine elicited significant mucosal cell-mediated immune responses in the lungs that limited lung viral replication. The presented results demonstrate that serum neutralizing humoral and local lung T-cell immune responses are critical for the control of SARS-CoV-2 replication.
Keyphrases
- sars cov
- immune response
- respiratory syndrome coronavirus
- dendritic cells
- toll like receptor
- escherichia coli
- single cell
- circulating tumor
- dengue virus
- magnetic resonance
- cell free
- early stage
- single molecule
- magnetic resonance imaging
- coronavirus disease
- stem cells
- computed tomography
- bone marrow
- contrast enhanced
- brain injury